X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VYN202 is a potential best-in-class oral small molecule BD2-Selective BET inhibitor recently got IND approval by FDA for the treatment of psoriasis and rheumatoid arthritis.
Lead Product(s): VYN202
Therapeutic Area: Dermatology Product Name: VYN202
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Details:
VYN201 is a pan-bromodomain BET inhibitor designed to be locally-administered as a “soft” drug. It is being evaluated in phase 1 clinical trials for the treatment of nonsegmental vitiligo.
Lead Product(s): VYN201
Therapeutic Area: Dermatology Product Name: VYN201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
The net proceeds from this financing will fund through critical milestones, including the advancement of VYN201 into a Phase 2b clinical trial in vitiligo and Phase 1 trials for VYN202, BD2-selective BET inhibitor.
Lead Product(s): VYN201
Therapeutic Area: Dermatology Product Name: VYN201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LifeSci Capital LLC
Deal Size: $88.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 01, 2023
Details:
The net proceeds from this financing will fund through critical milestones, including the advancement of VYN201 into a Phase 2b clinical trial in vitiligo and Phase 1 trials for VYN202, BD2-selective BET inhibitor.
Lead Product(s): VYN201
Therapeutic Area: Dermatology Product Name: VYN201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Access Biotechnology
Deal Size: $88.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 30, 2023
Details:
VYN202 is a potential best-in-class oral small molecule BD2-Selective BET inhibitor today announced results for preclinical models of psoriasis and rheumatoid arthritis.
Lead Product(s): VYN202
Therapeutic Area: Dermatology Product Name: VYN202
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
VYN201 is a locally-administered pan-bromodomain BET inhibitor, designed as a “soft” drug for diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. The drug is currently being studied for vitiligo.
Lead Product(s): VYN201
Therapeutic Area: Dermatology Product Name: VYN201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
VYN202 is a potential best-in-class oral small molecule BD2-Selective BET inhibitor for the treatment of immuno-inflammatory conditions like RA, crohn's disease etc.
Lead Product(s): VYN202
Therapeutic Area: Immunology Product Name: VYN202
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
VYN201 is a locally-administered pan-bromodomain BET inhibitor, designed to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. it is being investigated for idiopathic pulmonary fibrosis.
Lead Product(s): VYN201
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: VYN201
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2023
Details:
VYN201 is a locally-administered pan-bromodomain BET inhibitor, designed to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. It is being investigated for vitiligo.
Lead Product(s): VYN201
Therapeutic Area: Dermatology Product Name: VYN201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
VYN201 is a locally-administered pan-bromodomain BET inhibitor, designed to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. It is being investigated for vitiligo.
Lead Product(s): VYN201
Therapeutic Area: Dermatology Product Name: VYN201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
